Pharma Sector Surge: US FDA Clearances and Domestic Formulations Power Gains

Sector Highlights

Indian drug manufacturers—led by Sun Pharma, Cipla, and Mankind Pharma—are witnessing accelerating momentum as US generic price erosion stabilizes and domestic chronic prescription segments maintain robust margins.

Key Strengths

1. US FDA Compliance: Major manufacturing facilities have cleared regulatory audits with minimal observations, removing regulatory overhangs.
2. Specialty Portfolios: High-margin biosimilar and dermatological pipelines are contributing significantly to international gross revenues.

Technical Setup

The Nifty Pharma index remains in a defined multi-month upward channel, reflecting continuous institutional accumulation.